anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for obtaining a recombinant myeloma cell clone in a protein-free culture medium. The method includes recombining a myeloma cell line, the process from the serum-free medium to the protein-free culture medium cannot be finished or can be finished with a long time, and the antibody yield is reduced due to the existence of the non-growth cell population. The method includes the gradual adapting process from low concentration to high concentration in the protein-free culture medium. The phenotypic adaptation cultured with high cell density in the protein-free culture medium is along with the increases of the recombinant antibody molecule secretion rate and the high-yield stable expression cell clone percentage. A humanized anti-NeuGcGM3 14F7h recombinant antibody can be prepared according to the cell clone disclosed in the invention. Furthermore, the attributive character of the humanized anti-NeuGcGM3 recombinant antibody14F7hare is also disclosed in the invention.
The invention belongs to the technical field of biomarkers, and particularly relates to a biomarker for cerebral apoplexy recurrence risk analysis and application thereof. The biomarker is a Notch1 ligand. The Notch1 ligand comprises one or two of DLL1 and Jagged 1. The invention provides a biomarker for cerebral apoplexy recurrence risk analysis and application thereof. By means of the biomarkers, cerebral apoplexy recurrence risk analysis reagent or kit can be prepared to predict the risk of the patient suffering from acute ischemic cerebral apoplexy recurrence or monitor the occurrence of the patient or the patient suffering from acute ischemic cerebral apoplexy recurrence. The biomarker provided by the invention is favorable for better understanding pathophysiology of recurrent cerebral apoplexy, and provides new opportunities for diagnosis and prognosis, thereby improving clinical services of cerebral apoplexy patients.
The administration of propofol injectable emulsion should be initiated as a continuous infusion and changes in the rate of administration made slowly (>5 min) in order to minimize hypotension and avoid acute overdosage [see Overdosage (10) and Dosage and Administration (2.5)].

Patients should be monitored for early signs of significant hypotension and/or cardiovascular depression, which may be profound. These effects are responsive to discontinuation of propofol injectable emulsion, intravenous fluid administration, and/or vasopressor therapy. In the elderly, debilitated, or ASA-PS III or IV patients, rapid (single or repeated) bolus administration should not be used during sedation in order to minimize undesirable cardiorespiratory depression.

As with other sedative medications, there is wide interpatient variability in propofol injectable emulsion dosage requirements, and these requirements may change with time.

Failure to reduce the infusion rate in patients receiving propofol injectable emulsion for extended periods may result in excessively high blood concentrations of the drug. Thus, titration to clinical response and daily evaluation of sedation levels are important during use of propofol injectable emulsion infusion for ICU sedation, especially when it is used for long durations.

Opioids and paralytic agents should be discontinued and respiratory function optimized prior to weaning patients from mechanical ventilation. Infusions of propofol injectable emulsion should be adjusted to maintain a light level of sedation prior to weaning patients from mechanical ventilatory support. Throughout the weaning process, this level of sedation may be maintained in the absence of respiratory depression.

Abrupt discontinuation of propofol injectable emulsion prior to weaning or for daily evaluation of sedation levels should be avoided. This may result in rapid awakening with associated anxiety, agitation, and resistance to mechanical ventilation. It is therefore recommended that administration of propofol injectable emulsion be continued in order to maintain a light level of sedation throughout the weaning process until 10 to 15 minutes prior to extubation, at which time the infusion can be discontinued.
BACKGROUND: Osteosarcopenia is geriatric syndrome defined as the concomitant occurrence of osteopenia/osteoporosis, and sarcopenia. Osteosarcopenia is a relatively new concept in geriatric medicine; however, it may increase the risk of fragility fractures, several morbidities and mortalities, and socioeconomic costs. Although resistance exercises and nutritional support-including protein, calcium, and vitamin D-are potential non-pharmacological management procedures, evidence is still lacking. The objective of this study was therefore to evaluate the effect of combined resistance exercise and nutritional support on the quality and quantity of bone and muscle in postmenopausal females with osteosarcopenia.
METHODS: This research proposal presents the protocol for a prospective, single-center, single-blinded, two-armed randomized controlled trial. Thirty-four participants with osteosarcopenia will be recruited and randomly divided into intervention and control groups; both groups will receive nutritional supplements (protein, 40 g; vitamin D, 1600 IU; calcium, 600 mg) daily. The intervention group will undergo 24 weeks of resistance exercise of increasing intensity, achieved through a three-phase step-up process. The primary outcomes will be the changes in skeletal muscle index and bone marrow density of the lumbar spine and femoral neck between the baseline and end of intervention (24 weeks). The secondary outcomes will be the body composition, whole body phase angle, physical function assessment, quality of life, psychological assessment, and bone turnover markers of participants, surveyed at multiple time points.
DISCUSSION: This randomized controlled trial may reveal the effect of resistance exercise and nutritional support on older postmenopausal women with osteosarcopenia. The results will provide evidence for developing proper non-pharmacological management guidelines for postmenopausal women.
TRIAL REGISTRATION: Clinical Research Information Service of Republic of Korea, KCT0008291, Registered on 16 March 2023, https://cris.nih.go.kr/cris/search/detailSearch.do/25262 .
Nonepisodic angioedema with eosinophilia (NEAE) is characterised by a single episode of angioedema localised to the extremities and peripheral eosinophilia. While NEAE can develop in response to infection or vaccination, NEAE associated with acute parvovirus B19 (B19V) infection is rare. We describe the case of a young woman with NEAE that developed during acute B19V infection. She presented with 1-week history of pruritus and polyarthralgia in the extremities, followed by the development of peripheral oedema, and was positive for anti-B19V IgM antibody. Her arthralgia improved within 2 weeks without any specific intervention; however, the oedema and pruritic erythema persisted and the peripheral eosinophil count increased. A short course of prednisolone therapy for suspected NEAE alleviated the symptoms, which have not recurred for more than 2 years. Thus, we believe that the patient was affected by NEAE and that NEAE can develop following acute B19 infection.
Liver fibrosis, arising from factors such as viral infections or metabolic disorders, represents an ongoing global health challenge and is a major risk factor for hepatocellular carcinoma. Unfortunately, there are no clinically approved drugs available for its treatment. Recent studies have illuminated the pivotal role of macrophage recruitment in the pathogenesis of liver fibrosis, presenting a potential therapeutic target. Therefore, it holds great promise to develop novel anti-fibrotic therapies capable of inhibiting this process. Herein, a drug-loaded biomimetic nanodecoy (CNV-C) is developed by harnessing genetically engineered cellular vesicles for the treatment of liver fibrosis. CNV-C is equipped with a C-C motif chemokine receptor 2 (CCR2)-overexpressed surface, enabling it to selectively neutralize elevated levels of C-C motif chemokine ligand 2 (CCL2), thereby reducing macrophage infiltration and the subsequent production of the fibrogenic cytokine transforming growth factor β (TGF-β). Moreover, curcumin, an anti-fibrotic agent, is loaded into CNV-C and delivered to the liver, facilitating its efficacy in suppressing the activation of hepatic stellate cells by blocking the downstream TGF-β/Smad signaling. This combinational therapy ultimately culminates in the alleviation of liver fibrosis in a mouse model induced by carbon tetrachloride. Collectively, the findings provide groundbreaking proof-of-concept for employing genetically modified nanodecoys to manage liver fibrosis, which may usher in a new era of anti-fibrotic treatments.
Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
Nipah henipavirus (NiV) virus replicon particles (VRPs) are disclosed herein. These VRPs can be used to induce an immune response to NiV or Hendra virus (HeV). In some embodiments, the NiV VRP include a recombinant NiV genome, wherein the recombinant NiV genome comprises a deletion in a nucleic acid sequence encoding the F protein such that functional mature F protein cannot be produced from the recombinant NiV genome; and a NiV envelope comprising F, G and M proteins of NiV. These VRP can infect human cells but cannot produce NiV particles from the infected human cells. Immunogenic compositions including the NiV VRP are also disclosed. In some embodiments, methods are disclosed for producing NiV VRP. The use of the disclosed NiV VRP to induce an immune response is also disclosed.
Participants will have the routine rehabilitation protocol and as an addition participants will use a cuff placed proximal to the arm during upper extremity strengthening exercises. The cuff to be used is 175mm wide and 920mm long. After the cuff is placed, it will be inflated to the determined arterial occlusion pressure. The pressure will be adjusted to 50% of the BP in the arm during rest and increased to 60%. Exercises will be performed with the cuff inflated, at approximately 20-30% of 1RM. The first set will be 30 repetitions or at the limit of fatigue (maximum of 4/10), then three sets of 15 repetitions. The cuff will not be deflated for the 30 second rest between sets. A rehabilitation session will be held under the supervision of a physiotherapist. Exercise will be performed for 6 weeks with 3 sessions each week, with 1-2 days break between sessions.
Stabilization of hypoxia-inducible factor (HIF) by inhibiting prolyl hydroxylase domain enzymes (PHDs) represents a breakthrough in treating anemia associated with chronic kidney disease. Here, we identified a novel scaffold for noncarboxylic PHD inhibitors by utilizing structure-based drug design (SBDD) and generative models. Iterative optimization of potency and solubility resulted in compound 15 which potently inhibits PHD thus stabilizing HIF-α in vitro. X-ray cocrystal structure confirmed the binding model was distinct from previously reported carboxylic acid PHD inhibitors by pushing away the R383 and Y303 residues resulting in a larger inner subpocket. Furthermore, compound 15 demonstrated a favorable in vitro/in vivo absorption, distribution, metabolism, and excretion (ADME) profile, low drug-drug interaction risk, and clean early safety profiling. Functionally, oral administration of compound 15 at 10 mg/kg every day (QD) mitigated anemia in a 5/6 nephrectomy rat disease model.
524,515. Lactoflavin. NAAMLOOZE VENNOOTSCHAP ORGANON. Jan. 31, 1939, No. 3277. Convention date, Feb. 1, 1938. [Class 2 (iii)] Lactoflavin and lactoflavin phosphoric acid are separated by distribution between an aqueous solution and a phenyl-substituted alkanol or a mixture of a phenol with a hydrocarbon or aliphatic alcohol. In examples the two liquids are (1) sodium chloride solution and benzyl alcohol; (2) water and # phenylethyl methyl ethyl carbinol; (3) water and a mixture of phenol and isobutanol ; (4) an aqueous sodium chloride solution of lactoflavin and lactoflavin phosphoric acid is extracted with phenol which extracts both compounds ; then benzene is added and the whole is shaken with an equal volume of water which extracts the lactoflavin phosphoric acid, the lactoflavin remaining in the organic solvent mixture. The Specification as open to inspection under Sect. 91 is not limited to the solvents defined above but includes distribution between any two immersible solvents both of which may be organic. This subject-matter does not appear in the Specification as accepted.
OBJECTIVES: The primary objective was to compare sensory processing measures in people attending specialist orthopaedic consultation for management of persistent shoulder pain with control participants. The secondary objective was to compare the groups' sociodemographic, clinical, general health and lifestyle, and psychological characteristics. DESIGN: Observational cross-sectional. METHODS: Participants with shoulder pain for ≥3 months, who attended a public hospital orthopaedic department (n = 119), and community participants without shoulder pain (n = 44) underwent a standardized quantitative sensory testing protocol, measuring pressure pain threshold, temporal summation, and conditioned pain modulation. Sociodemographic, clinical, general health and lifestyle, and psychological characteristics were also collected. RESULTS: Participants with shoulder pain had significantly lower pressure pain thresholds at all sites (ie, local and widespread mechanical hyperalgesia) and significantly decreased conditioned pain modulation effect (ie, descending inhibition of nociception) than control participants. There was no significant difference between groups for temporal summation. Participants with shoulder pain had decreased general health and function, less healthy lifestyles, and poorer psychological health compared with controls. CONCLUSION: People referred to specialist orthopaedic care for management of persistent shoulder pain had clinical signs of altered sensory processing and poor health outcomes. J Orthop Sports Phys Ther 2024;54(10):1-10. Epub 25 July 2024. doi:10.2519/jospt.2024.12512.
Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
INTRODUCTION: We aimed to provide a pathological perspective on the management of muscle-invasive bladder cancer (MIBC) by correlating the prechemotherapy transurethral resection of bladder tumor findings and postchemotherapy radiologic evaluation with final radical cystectomy (RC) findings.
MATERIALS AND METHODS: This retrospective study included 79 MIBC patients treated with neoadjuvant chemotherapy (NAC) and RC. Pelvic diffusion-weighted magnetic resonance imaging (DW-MRI) and pathologic reports were retrieved from our institutional database. All pathology slides were reviewed based on diagnostic criteria with high interobserver reproducibility.
RESULTS: Pathologic complete response (pCR) was confirmed in 32 patients (40.5%). The concordance and discordance between MRI and RC findings occurred in 68.3% and 31.7% of cases, respectively. The 21.5% of cases that were clinical CR (cCR) on MRI actually achieved pCR on RC specimens and 46.8% of cases that were non-cCR on MRI were actually non-pCR on RC specimens. In 19.0% of cases, RC findings were pCR, but MRI demonstrated residual tumor and the opposite was 12.7%. The greatest discrepancy between the 2 methods (75%, 3/4) was for the plasmacytoid subtype. Plasmacytoid histology was the most common histological subtype identified in RC specimens after NAC, followed by micropapillary and squamous histologies.
CONCLUSIONS: We found that all cases with plasmacytoid and micropapillary subtypes, and squamous differentiation did not show pCR. In particular, the largest discrepancy between MRI findings and RC pathology after NAC was seen in the plasmacytoid subtype. An accurate pathologic diagnosis based on strict criteria to identify histological subtypes of MIBC is necessary for proper treatment.
BACKGROUND: Tenolysis restores mobility to the flexor tendon through the lysis of adhesions that inhibit and negatively impact functional outcomes following flexor tendon repair. Despite extensive literature on operative techniques and therapy protocols used to minimize adhesion formation, there are limited data examining the association of patient, injury, and postoperative factors with tenolysis. This study aims to: (1) quantify tenolysis rates following flexor tendon repair or reconstruction; and (2) identify patient demographic factors, medical comorbidities, injury characteristics, postoperative diagnoses, and complications associated with tenolysis.
METHODS: PearlDiver was used to identify patients who underwent a flexor tendon repair or reconstruction from 2010 to 2020. Patients were stratified by whether or not flexor tenolysis was performed. Patient demographics, comorbidities, injury characteristics, postoperative diagnoses, and complications were recorded. Logistic regression analysis was used to identify independent risk factors associated with tenolysis.
RESULTS: Database review identified 10 264 patients who underwent either flexor tendon repair or reconstruction, with 612 patients (6.0%) subsequently undergoing tenolysis. Logistic regression analysis determined that vascular injury preceding flexor tendon repair, surgical wound disruption, nerve injury diagnosed postoperatively, postoperative tendon rupture, and need for repeat flexor tendon repair were associated with an increased odds of tenolysis. Patient age, sex, and comorbidities were not associated with performance of tenolysis.
CONCLUSIONS: Although tenolysis rates may differ according to physician and patient preferences, identification of factors associated with tenolysis following flexor tendon repair allows surgeons to risk-stratify patients prior to surgery and help guide postoperative expectations if complications arise.
Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
The invention discloses a production method of sterile stable azithromycin eye drops. The sterile stable azithromycin eye drops comprise a sterile solid drug packaged individually and a special-purpose solvent for dissolving the sterile solid drug. The sterile solid drug contains an active component and pharmaceutically acceptable auxiliary materials. The active component is azithromycin. According to the production method, the active component azithromycin and the pharmaceutically acceptable auxiliary materials are prepared into sterile freeze-dried powder and the sterile freeze-dried powder is dissolved in the special-purpose sterile solvent in clinical use. The production method can improve stability of the azithromycin eye drops, realize production of the sterile stable azithromycin eye drops, and improve safety of the sterile stable azithromycin eye drops in use.
The invention relates to traditional Chinese medicine prepared from Chinese herbal medicine for treating endocrine dyscrasia. The traditional Chinese medicine is prepared from the following bulk pharmaceuticals in parts by weight: 3-5 parts of saffron, 10-15 parts of semen pharbitidis, 10-15 parts of rhubarb, 10-15 parts of medicated leaven, 10-15 parts of Chinese angelica, 10-15 parts of Szechuan lovage rhizome, 5-10 parts oftalc powder and 5-10 parts of white paeony root. The bulk pharmaceuticals can be prepared into any conventional oral dosage form, preferably powder and honeyed boluses by adopting the conventional pharmacy method. The traditional Chinese medicine has the effects of dispersing five types of blood stasis, regulating qi and blood, eliminating cold phlehm, promoting appetite and regulating gastrointestinal functions. Through six generations of passage and years of clinical practice of the applicant, the traditional Chinese medicine has good curative effects on woman infertility, gynecological inflammation, various types of continuous bleeding, excessive multicolored vaginal discharge, chaotic menstruation and amenorrhea. The traditional Chinese medicine has good curative effects on patients suffering from endocrine dyscrasia such as gastric acid, gastric distention and fullness, constipation, saccharide discharge, stomachache, numbness of the limbs, low back and leg pain, insomnia or hypersomnia, emaciation or obesity, postmenopausal bleeding and private swelling and itching of the aged, alopecia, less growth of new hairs, balding and light color, inappetence, gingival bleeding, ozostomia and nightmare. Moreover, the traditional Chinese medicine does not cause any toxic or side effect after being taken for a long time, and does not have drug tolerance.
A syringe pump includes a lead screw, a motor, and a sliding block assembly. The lead screw has threads and the motor is coupled to the lead screw to rotate it. The half-nut housing has a half nut and a barrel cam. The half nut is disposed within the half-nut housing. The half nut has half-nut threads at an end adjacent to the lead screw void. The half nut engages or disengages with the threads of the lead screw. The half nut includes a half-nut cam-follower surface and a half nut slot. The barrel cam is disposed within the half-nut housing and engages with the half-nut cam-follower surface. The barrel cam includes a pin to fit within the half nut slot such that the barrel cam rotates between a first position and a second position to actuate the half nut between the engagement position and the disengagement position, respectively.
PURPOSE:To obtain a discoloration-resistant antimicrobial zeolite-containing composition prevented from discoloration without reducing its antimicrobial properties by adding a discoloration-preventing agent, especially an oxide having a discoloration-preventing effect to an antimicrobial zeolite-containing composition before processing, molding, heating and an exothermic reaction. CONSTITUTION:An antimicrobial zeolite-containing composition containing a discoloration-preventing agent. As the discoloration-preventing agent used here, an reduction inhibitor for an antimicrobial zeolite-derived antimicrobial metal ion, especially an oxidizing agent and, above all, antimony pentachloride are preferable. This discoloration-preventing agent is used preferably in an amount of 0.05 to 10.0wt.% and a resin composition is recommendably used as this composition. One selected from a group of a photosetting resin composition, a cold setting resin composition and a thermosetting resin composition is especially preferably used as the resin composition. Even in the case of additional polymerization of a starved-area, this composition can be reheated without colloidizing metal ions in the resin composition in which polymerization was already completed.